Kanaph

Developer of immunocytokine platform for treating cancer

placeSeoul, Seoul, South Korea calendar_todayFounded 2019 groups13 employees language kanaphtx.com

Innovation

1 patent family — focus: Operations & transport; filing pace slowing. Cited 9 times.

YearFilings
20221

Investor mix

4 investors on record; lead investors include Meritz Securities, Time Polio Asset Management, Green Cross, Kolon Investments.

Investor typeCountShare
Private equity125%
Other / undisclosed375%
Coming soon